The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.50
Bid: 12.50
Ask: 13.50
Change: 5.575 (75.08%)
Spread: 1.00 (8.00%)
Open: 9.65
High: 13.50
Low: 9.65
Prev. Close: 7.425
CAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

18 Oct 2022 07:00

RNS Number : 1741D
Carclo plc
18 October 2022
 

 

18 October 2022

 

 

Carclo plc

 

("Carclo" or the "Group")

 

Trading Update

 

Carclo, a global manufacturer, principally of fine tolerance injection moulded plastic parts and aerospace components, publishes the following trading update for the first six months of its financial year ending 31 March 2023 ("FY23").

 

Demand has remained strong in our chosen sectors and, as a result, Group sales were marginally ahead of the Board's expectations and ahead of the prior year.

 

The Life Sciences sector within CTP, comprising Medical and Diagnostic customers, continued to deliver good revenue growth, despite delays in the ramp-up of volumes on two new product lines. The benefit of this revenue growth was offset by a decrease in margins, driven by a combination of costs associated with the introduction of new products and, as predicted, inflationary and supply chain cost pressures. These cost pressures are being offset by price increases wherever possible. The management team has been further strengthened to focus on improving operational efficiency.

 

The Aerospace sector traded strongly in the first half with continued high order intake and significant sales growth. Inflationary pressures have been effectively mitigated and as a result margins have been maintained at prior-year levels.

 

As a result, underlying Operating Profit for the Group is in line with the Board's expectation and marginally below the prior year, supported by favourable exchange rate movements, particularly the movement of sterling against the US dollar.

 

An extension of the Group's financing agreements was also completed in the first half with bank facilities committed out to June 2025. Net debt increased in the half year largely driven by higher working capital and investment in capital equipment to support future growth. The Group pension scheme IAS 19 accounting deficit has reduced slightly since March 2022, with both asset and liability values reducing significantly during recent high volatility in equity and bond markets.

 

The inflation and supply chain challenges experienced in the first half are expected to continue through the remainder of the financial year. Our initiatives to further enhance operational efficiency and to offset inflationary price increases are key focus areas for the second half. Increases in borrowing costs are expected in the second half driven by increases in both the level of debt and interest rates.

 

Carclo plans to announce its interim results for the six months to 30 September 2022 in November 2022.

 

About Carclo plc

Carclo plc is a public company whose shares are quoted on the Main Market of the London Stock Exchange. The Group is a global provider of value-adding engineered solutions for the medical, optical and aerospace industries.

 

LEI: 21380078MEM399JPI956

 

Enquiries:

Carclo plc

01924 268040

Frank Doorenbosch

CEO

Phil White

CFO

FTI Consulting

020 3727 1340

Nick Hasell / Susanne Yule

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFITIDLDLIF
Date   Source Headline
26th Apr 20247:00 amRNSTrading Statement
17th Apr 20247:55 amRNSDirectorate Change
15th Apr 20243:55 pmRNSHolding(s) in Company
28th Feb 20247:00 amRNSDirectorate Change
14th Feb 20247:00 amRNSStrategic Consolidation & Tucson Facility Closure
9th Feb 20241:15 pmRNSHolding(s) in Company
29th Jan 202411:09 amRNSDirectorate Change
23rd Jan 20244:48 pmRNSHolding(s) in Company
6th Dec 202310:53 amRNSHolding(s) in Company
30th Nov 20237:00 amRNSHalf-year Report
16th Nov 20237:00 amRNSNotice of Interim Results & Investor Presentation
25th Oct 20233:16 pmRNSCarclo Strategic Decision to Close Derry Facility
22nd Sep 20237:00 amRNSDirector/PDMR Shareholding
31st Aug 20234:01 pmRNSResult of AGM
31st Aug 20237:00 amRNSTrading Update
21st Aug 20231:09 pmRNSDirectorate Change
31st Jul 202311:42 amRNSAnnual Financial Report
18th Jul 20237:00 amRNSBanking covenant update
12th Jul 20237:00 amRNSFinal Results
7th Jul 20237:00 amRNSNotice of Investor Meet Presentation
23rd Jun 20237:00 amRNSBanking covenant adjustment
21st Jun 20231:08 pmRNSNotice of Results
30th May 202310:07 amRNSUpdate on contract cancellation
17th May 20238:46 amRNSHolding(s) in Company
12th May 20239:38 amRNSHolding(s) in Company
14th Apr 20237:00 amRNSTrading Statement
31st Mar 202312:50 pmRNSBanking Covenant update
9th Mar 20239:56 amRNSHolding(s) in Company
24th Feb 20237:00 amRNSDirectorate Change
6th Jan 20234:17 pmRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20221:15 pmRNSDirector/PDMR Shareholding
16th Dec 20221:11 pmRNSDirector/PDMR Shareholding
16th Dec 20221:10 pmRNSDirector/PDMR Shareholding
15th Dec 20227:00 amRNSTrading Update
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 20229:44 amRNSContract Cancellation
6th Dec 20226:29 pmRNSHolding(s) in Company - Replacement
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
30th Nov 20227:00 amRNSHalf-year Report
15th Nov 20227:05 amRNSNotice of Interim Results & Investor Presentation
15th Nov 20227:00 amRNSDirectorate Change
7th Nov 20227:00 amRNSBoard Changes
18th Oct 20227:00 amRNSTrading Update
13th Oct 20221:22 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.